Shamburg News · 8-K filed Nov 10, 2026, 4:10 PM EST
Atara Biotherapeutics Reports Q3 2026 Net Loss of $2.2 Million on Revenue of $1.2 Million
ATRA · Atara Biotherapeutics, Inc.
- Earnings
- Materiality: high
Atara Biotherapeutics reported a third quarter 2026 net loss of $2.2 million, or $(0.15) per basic and diluted share, compared with a net loss of $4.3 million, or $(0.32) per share, a year earlier. Total revenues were $1.2 million, down from $3.5 million, primarily due to a one-time sale of clinical inventory in the prior year. Cash, cash equivalents and short-term investments totaled $9.9 million as of September 30, 2026, which the company said will fund planned operations into mid-2027; the tab-cel BLA has a PDUFA target action date of March 31, 2027.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001104659-26-125171.
Written from the filing by Shamburg Markets. Figures are as reported by the company.